Repare Therapeutics' Lunresertib (RP-6306) Phase 1 MINOTAUR Study Data To Be Presented At ESMO 2024

5/29/24 7:19:35 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RPTX alert in real time by email

Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib (RP-6306) in combination with FOLFIRI for the treatment of advanced solid tumors has been selected for a poster presentation at the European Society of Medical Oncology (ESMO) Gastrointestinal (GI) Cancers Congress 2024, being held June 26-29 in Munich, Germany.

Get the next $RPTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RPTX

Date	Price Target	Rating	Analyst
6/9/2023	$11.00 → $16.00	Hold → Buy	Stifel
2/3/2023	$28.00 → $15.00	Overweight → Equal-Weight	Morgan Stanley
1/6/2023	$28.00	Overweight	CapitalOne
4/12/2022	$11.00	Buy → Hold	Stifel
3/17/2022	$43.00	Buy	Goldman
9/23/2021	$48.00	Buy	Stifel
9/13/2021	$54.00	Buy	HC Wainwright & Co.
8/16/2021	$45.00 → $47.00	Overweight	Morgan Stanley

More analyst ratings

$RPTX
Press Releases

Fastest customizable press release news feed in the world

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced a Cooperative Research and Development Agreement (CRADA) has been executed to advance the development of camonsertib as an anticancer agent in collaboration with the Cancer Therapy Evaluation Program (CTEP) of the US National Cancer Institute (NCI), part of the US National Institutes of Health. "This partnership with the CTEP allows the research community to investigate the full clinical potential of camonsertib more easily and we believe it will provide additional clinical development catalysts for the program," said Lloyd M. Segal, President and Chief
11/12/24 7:05:00 AM ET
$RPTX
Biotechnology: Pharmaceutical Preparations
Health Care
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
On track to report data from the ongoing MYTHIC dose expansion clinical trial at the recommended Phase 2 dose (RP2D) at a company event in December 2024, with the plan to begin a registrational trial in 2025 Presented updated positive safety and tolerability results from the Phase 1 MYTHIC clinical trial at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Dosed first patient in Phase 1 POLAR trial evaluating RP-3467, a Polθ ATPase inhibitor, alone and in combination with the PARP inhibitor, olaparib Presented first-in-human data highlighting the clinical benefits of camonsertib in combination with radiotherapy at the ASTRO annual meeting Repare Therapeutics
11/7/24 7:05:00 AM ET
$RPTX
Biotechnology: Pharmaceutical Preparations
Health Care
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Data presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today presented updated data highlighting the benefits of its individualized schedule for the management of anemia in the Phase 1 MYTHIC clinical trial treating patients with the combination of lunresertib, a first-in-class PKMYT1 inhibitor, and camonsertib, a potential best-in-class oral small molecule ATR inhibitor (lunre+camo). Lunre+camo in the MYTHIC clinical trial (NCT04855656) previously demonstrated promising clinical activity in molecularly selected patients across multiple
10/23/24 6:05:00 AM ET
$RPTX
Biotechnology: Pharmaceutical Preparations
Health Care

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination with the WEE1 inhibitor, Debio 0123; first clinical trial inhibiting both PKMYT1 and WEE1 Initiating Phase 2 TRESR expansion in ~20 patients evaluating monotherapy camonsertib in NSCLC; initial data expected in 2025 First patient dosed in Phase 1 LIONS monotherapy trial for PLK4 inhibitor RP-1664 Announced the appointment of Steven H. Stein, M.D. to Repare's Board of Directors, effecti
5/7/24 4:05:00 PM ET
$RPTX
Biotechnology: Pharmaceutical Preparations
Health Care
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company's upcoming annual meeting of shareholders in June 2024. The Company also announces that Todd Foley has decided not to stand for re-election as a director of the Company following the end of his current term as a Class I director on June 17, 2024, after serving more than seven years on the Board. "On behalf of the Company and our Board of Directors, we thank Todd for his dedication and partnership, which have played a crucial role in shaping Repare
4/26/24 4:05:00 PM ET
$RPTX
Biotechnology: Pharmaceutical Preparations
Health Care
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024. "We significantly advanced our pipeline in 2023 and presented strong data from key programs, notably for lunresertib in combination with camonsertib, and for camonsertib in combination with PARP inhibitors. In addition, we presented compelling preclinical data sets for RP-3467, which we're developing as a potential best-in-class Polθ inhibitor, and for RP-1664, a potential first- and best-in-class PLK4 inhibitor," said Lloyd M. Segal, President and Chief Executive Officer of Repare. "2
1/8/24 7:00:00 AM ET
$RPTX
Biotechnology: Pharmaceutical Preparations
Health Care

$RPTX
Market Insights

Live Market Insights

Repare Therapeutics Shares Initial Data From Phase 1 MINOTAUR Trial Evaluating Lunresertib In Combination With FOLFIRI At ESMO GI Cancers Congress 2024
Overall response of 18.2% in heavily pretreated patients across gastrointestinal tumors with target alterations regardless of prior irinotecan exposureProlonged clinical benefit in patients with CRC, with 40% of irinotecan-naïve patients receiving treatment for greater than nine monthsPreliminary RP2D established as 60mg BID lunresertib continuous plus standard FOLFIRISafety profile of combination consistent with FOLFIRI aloneRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reported positive initial data from the ongoing Phase 1 MINOTAUR clinical trial evaluating lunresertib (RP-6306) in combination with FOLFIRI in
6/26/24 10:33:20 AM ET
$RPTX
Biotechnology: Pharmaceutical Preparations
Health Care
Foundation Medicine Taps Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
Foundation Medicine, Inc., today announced that it has formed a collaboration with Repare Therapeutics, a leading clinical-stage precision oncology company, to provide prospective genomic profiling to patients in Repare’s ongoing Phase I/Ib MYTHIC study (NCT04855656) of lunresertib alone or in combinations in genomically-defined patient populations. The companies are also exploring opportunities to develop FoundationOne®CDx, a tissue-based comprehensive genomic profiling test, as a companion diagnostic for the lunresertib program.
6/12/24 7:17:29 AM ET
$RPTX
Biotechnology: Pharmaceutical Preparations
Health Care
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company's camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of the TRESR clinical trial.
6/10/24 7:09:17 AM ET
$RPTX
Biotechnology: Pharmaceutical Preparations
Health Care

$RPTX
Financials

Live finance-specific insights

The Week in Canadian Press Releases: 10 Stories You Need to See
A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, May 31, 2024 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that
5/31/24 6:18:00 AM ET
$CM
$RPTX
$RY
Commercial Banks
Finance
Biotechnology: Pharmaceutical Preparations
Health Care
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
RP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-high tumor cells in preclinical studies RP-3467 demonstrated complete, sustained regressions preclinically in combination with PARPi, and compelling anti-tumor activity in combination with radioligand therapy (RLT) and chemotherapy Company expects to initiate clinical trials of RP-1664 in 1H 2024 and RP-3467 in 2H 2024 Repare to host conference call and webcast today at 8:00 a.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today disclosed polo-like kinase 4 (PLK4) as the target of its RP-1664 development progra
11/15/23 7:00:00 AM ET
$RPTX
Biotechnology: Pharmaceutical Preparations
Health Care
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Presented positive initial data from ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, including an overall RECIST response rate of 50% in patients with heavily pre-treated gynecological tumors Repare to host conference call and webcast to discuss latest data from its preclinical programs and overall pipeline, November 15th, 2023 at 8:00 a.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023. "We substantially advanced our pipeline during the third quarter, particularly our Phase
11/9/23 7:00:00 AM ET
$RPTX
Biotechnology: Pharmaceutical Preparations
Health Care

Repare Therapeutics' Lunresertib (RP-6306) Phase 1 MINOTAUR Study Data To Be Presented At ESMO 2024

Chat with this insight

Recent Analyst Ratings for $RPTX

$RPTX Press Releases

Fastest customizable press release news feed in the world

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

$RPTX SEC Filings

SEC Form 424B5 filed by Repare Therapeutics Inc.

SEC Form 10-Q filed by Repare Therapeutics Inc.

Repare Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$RPTX Leadership Updates

Live Leadership Updates

$RPTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors

Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

SEC Form 4 filed by Director Schafer Carol

SEC Form 4 filed by Director Morrison Briggs

SEC Form 4 filed by Director Rhoads Ann D

$RPTX Market Insights

Live Market Insights

Repare Therapeutics Shares Initial Data From Phase 1 MINOTAUR Trial Evaluating Lunresertib In Combination With FOLFIRI At ESMO GI Cancers Congress 2024

Foundation Medicine Taps Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

$RPTX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$RPTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$RPTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Bvf Partners L P/Il bought $6,249,889 worth of shares (1,227,301 units at $5.09) (SEC Form 4)

Bvf Partners L P/Il bought $2,821,352 worth of shares (783,709 units at $3.60) (SEC Form 4)

Repare Therapeutics upgraded by Stifel with a new price target

Repare Therapeutics downgraded by Morgan Stanley with a new price target

CapitalOne initiated coverage on Repare Therapeutics with a new price target

Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

$RPTX Financials

Live finance-specific insights

The Week in Canadian Press Releases: 10 Stories You Need to See

Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Recent Analyst Ratings for
$RPTX

$RPTX
Press Releases

$RPTX
SEC Filings

$RPTX
Leadership Updates

$RPTX
Insider Trading

$RPTX
Market Insights

$RPTX
Insider Purchases

$RPTX
Analyst Ratings

$RPTX
Large Ownership Changes

$RPTX
Financials